# Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)

> **NCT03891576** · PHASE2 · TERMINATED · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 83 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT03891576
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-13
- **Primary completion:** 2024-08-31
- **Final completion:** 2024-08-31
- **Target enrollment:** 83 (ACTUAL)
- **Why stopped:** Low accrual rate
- **Last updated:** 2025-01-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03891576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03891576, "Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03891576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*